71 related articles for article (PubMed ID: 8387118)
1. [Clinical application of retinoic acid and vitamin D3 derivatives to the treatment of refractory anemias].
Yoshida Y
Nihon Rinsho; 1993 Apr; 51(4):1023-8. PubMed ID: 8387118
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.
Greenberg BR; Durie BG; Barnett TC; Meyskens FL
Cancer Treat Rep; 1985 Dec; 69(12):1369-74. PubMed ID: 3865701
[TBL] [Abstract][Full Text] [Related]
3. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
4. [Retrospective observation of curative effects on MDS refractory anemia with combination of all-trans retinoic acid, 1, 25-dihydroxyvitamin D3 and androgen].
Zhou FL; Zhang WG; Cao XM; Chen YX; He AL; Liu J; Zhao WH; Ma XR; Chen G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):861-6. PubMed ID: 16277859
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lenalidomide in myelodysplastic syndromes.
List A; Kurtin S; Roe DJ; Buresh A; Mahadevan D; Fuchs D; Rimsza L; Heaton R; Knight R; Zeldis JB
N Engl J Med; 2005 Feb; 352(6):549-57. PubMed ID: 15703420
[TBL] [Abstract][Full Text] [Related]
6. [Simple refractory anemia. Response to treatment using maturative factors].
Rovira M; Feliu E; Sierra J; Boccia A; Aguilar JL; Vives-Corrons JL; Rozman C
Med Clin (Barc); 1989 Nov; 93(14):546-7. PubMed ID: 2622253
[TBL] [Abstract][Full Text] [Related]
7. Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome.
Takami A; Asakura H; Nakao S
Ann Hematol; 2002 Jan; 81(1):16-9. PubMed ID: 11807630
[TBL] [Abstract][Full Text] [Related]
8. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
9. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
10. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Suwanawiboon B; Sumida KN
Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
[TBL] [Abstract][Full Text] [Related]
11. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplasic syndromes: a comprehensive review.
Catenacci DV; Schiller GJ
Blood Rev; 2005 Nov; 19(6):301-19. PubMed ID: 15885860
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic growth factors in myelodysplastic syndromes.
Blinder VS; Roboz GJ
Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 [1 alpha(OH)D3]].
Irino S; Taoka T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1183-90. PubMed ID: 2837981
[TBL] [Abstract][Full Text] [Related]
15. Effect of 1,25-dihydroxyvitamin D3 and 13-cis-retinoic acid on in vitro hematopoiesis in the myelodysplastic syndromes.
Nagler A; Rikilis I; Tatarsky I; Fabian I
J Lab Clin Med; 1987 Aug; 110(2):237-44. PubMed ID: 3474327
[TBL] [Abstract][Full Text] [Related]
16. Refractory anemia and the myelodysplastic syndromes.
Lawrence LW
Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
[TBL] [Abstract][Full Text] [Related]
17. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies.
Selleri C; Maciejewski JP; Catalano L; Ricci P; Andretta C; Luciano L; Rotoli B
Cancer; 2002 Nov; 95(9):1911-22. PubMed ID: 12404285
[TBL] [Abstract][Full Text] [Related]
18. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
Maiolo AT; Foa P; Cortellaro M; Lambertenghi-Deliliers G; Colantoni A; Cesana B; Castoldi GL; Cazzola M; Giordano M; Riccardi A
Haematologica; 1987; 72(1):61-5. PubMed ID: 3108098
[No Abstract] [Full Text] [Related]
19. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation in myelodysplastic syndromes.
Sekeres MA; List A
Best Pract Res Clin Haematol; 2006; 19(4):757-67. PubMed ID: 16997181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]